These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15341487)

  • 1. N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy.
    Tavares FX; Boucheron JA; Dickerson SH; Griffin RJ; Preugschat F; Thomson SA; Wang TY; Zhou HQ
    J Med Chem; 2004 Sep; 47(19):4716-30. PubMed ID: 15341487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory mode of N-phenyl-4-pyrazolo[1,5-b] pyridazin-3-ylpyrimidin-2-amine series derivatives against GSK-3: molecular docking and 3D-QSAR analyses.
    Xiao J; Guo Z; Guo Y; Chu F; Sun P
    Protein Eng Des Sel; 2006 Feb; 19(2):47-54. PubMed ID: 16339768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.
    Kuo GH; Prouty C; DeAngelis A; Shen L; O'Neill DJ; Shah C; Connolly PJ; Murray WV; Conway BR; Cheung P; Westover L; Xu JZ; Look RA; Demarest KT; Emanuel S; Middleton SA; Jolliffe L; Beavers MP; Chen X
    J Med Chem; 2003 Sep; 46(19):4021-31. PubMed ID: 12954055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-Acylamino-6-arylfuro[2,3-d]pyrimidines: potent and selective glycogen synthase kinase-3 inhibitors.
    Maeda Y; Nakano M; Sato H; Miyazaki Y; Schweiker SL; Smith JL; Truesdale AT
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3907-11. PubMed ID: 15225695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors.
    Byth KF; Cooper N; Culshaw JD; Heaton DW; Oakes SE; Minshull CA; Norman RA; Pauptit RA; Tucker JA; Breed J; Pannifer A; Rowsell S; Stanway JJ; Valentine AL; Thomas AP
    Bioorg Med Chem Lett; 2004 May; 14(9):2249-52. PubMed ID: 15081018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel GSK-3 inhibitors with improved cellular activity.
    Peat AJ; Garrido D; Boucheron JA; Schweiker SL; Dickerson SH; Wilson JR; Wang TY; Thomson SA
    Bioorg Med Chem Lett; 2004 May; 14(9):2127-30. PubMed ID: 15080993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SAR studies of pyridazinone derivatives as novel glucan synthase inhibitors.
    Zhou G; Ting PC; Aslanian R; Cao J; Kim DW; Kuang R; Lee JF; Schwerdt J; Wu H; Herr RJ; Zych AJ; Yang J; Lam S; Wainhaus S; Black TA; McNicholas PM; Xu Y; Walker SS
    Bioorg Med Chem Lett; 2011 May; 21(10):2890-3. PubMed ID: 21489787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The synthesis and structure-activity relationship of pyridazinones as glucan synthase inhibitors.
    Ting PC; Kuang R; Wu H; Aslanian RG; Cao J; Kim DW; Lee JF; Schwerdt J; Zhou G; Wainhaus S; Black TA; Cacciapuoti A; McNicholas PM; Xu Y; Walker SS
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1819-22. PubMed ID: 21316223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selectivity criterion for pyrazolo[3,4-b]pyrid[az]ine derivatives as GSK-3 inhibitors: CoMFA and molecular docking studies.
    Patel DS; Bharatam PV
    Eur J Med Chem; 2008 May; 43(5):949-57. PubMed ID: 17707953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase.
    Bilodeau MT; Rodman LD; McGaughey GB; Coll KE; Koester TJ; Hoffman WF; Hungate RW; Kendall RL; McFall RC; Rickert KW; Rutledge RZ; Thomas KA
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2941-5. PubMed ID: 15125964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors.
    Peat AJ; Boucheron JA; Dickerson SH; Garrido D; Mills W; Peckham J; Preugschat F; Smalley T; Schweiker SL; Wilson JR; Wang TY; Zhou HQ; Thomson SA
    Bioorg Med Chem Lett; 2004 May; 14(9):2121-5. PubMed ID: 15080992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.
    Tamayo N; Liao L; Goldberg M; Powers D; Tudor YY; Yu V; Wong LM; Henkle B; Middleton S; Syed R; Harvey T; Jang G; Hungate R; Dominguez C
    Bioorg Med Chem Lett; 2005 May; 15(9):2409-13. PubMed ID: 15837335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiazolo[5,4-f]quinazolin-9-ones, inhibitors of glycogen synthase kinase-3.
    Testard A; Logé C; Léger B; Robert JM; Lozach O; Blairvacq M; Meijer L; Thiéry V; Besson T
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3419-23. PubMed ID: 16644220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and in vitro characterization of 1-(4-aminofurazan-3-yl)-5-dialkylaminomethyl-1H-[1,2,3]triazole-4-carboxylic acid derivatives. A new class of selective GSK-3 inhibitors.
    Olesen PH; Sørensen AR; Ursø B; Kurtzhals P; Bowler AN; Ehrbar U; Hansen BF
    J Med Chem; 2003 Jul; 46(15):3333-41. PubMed ID: 12852764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle.
    Kaidanovich-Beilin O; Eldar-Finkelman H
    J Pharmacol Exp Ther; 2006 Jan; 316(1):17-24. PubMed ID: 16169938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction.
    Giovannoni MP; Vergelli C; Biancalani C; Cesari N; Graziano A; Biagini P; Gracia J; Gavaldà A; Dal Piaz V
    J Med Chem; 2006 Aug; 49(17):5363-71. PubMed ID: 16913726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.
    Polychronopoulos P; Magiatis P; Skaltsounis AL; Myrianthopoulos V; Mikros E; Tarricone A; Musacchio A; Roe SM; Pearl L; Leost M; Greengard P; Meijer L
    J Med Chem; 2004 Feb; 47(4):935-46. PubMed ID: 14761195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.
    Lo Monte F; Kramer T; Gu J; Anumala UR; Marinelli L; La Pietra V; Novellino E; Franco B; Demedts D; Van Leuven F; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B
    J Med Chem; 2012 May; 55(9):4407-24. PubMed ID: 22533818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 9-cyano-1-azapaullone (cazpaullone), a glycogen synthase kinase-3 (GSK-3) inhibitor activating pancreatic beta cell protection and replication.
    Stukenbrock H; Mussmann R; Geese M; Ferandin Y; Lozach O; Lemcke T; Kegel S; Lomow A; Burk U; Dohrmann C; Meijer L; Austen M; Kunick C
    J Med Chem; 2008 Apr; 51(7):2196-207. PubMed ID: 18345612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases.
    Braña MF; Cacho M; García ML; Mayoral EP; López B; de Pascual-Teresa B; Ramos A; Acero N; Llinares F; Muñoz-Mingarro D; Lozach O; Meijer L
    J Med Chem; 2005 Nov; 48(22):6843-54. PubMed ID: 16250643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.